Have a personal or library account? Click to login
Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radiotherapy Cover

Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radiotherapy

Open Access
|Oct 2019

Abstract

This observational clinical study was composed of two substudies: a non-comparative one (n = 166), testing only lysozyme-based compounds (LBCs), and a comparative substudy (n = 275), testing both LBCs and bicarbonate-based local compounds (BBCs) on the healing of oral mucositis during radio- or chemotherapy. The density of ulcerations has decreased significantly after the treatment with lysozyme in both substudies. The density of ulcerations in the radiotherapy group was lower in patients treated with LBCs compared to patients treated with BBCs (p < 0.001). In the chemotherapy group, reduction of ulceration density was similar with both LBCs and BBCs. The LBCs reduced pain intensity during the intake of solid food and speech more than BBCs in both patient cohorts (p < 0.05). In the radiotherapy cohort, pain intensity when consuming liquid foods was reduced more with LBCs than with BBCs (p < 0.05). No adverse events were recorded. This study demonstrates the advantages of treating oral mucositis during radiotherapy or chemo-therapy with LBCs.

DOI: https://doi.org/10.2478/acph-2019-0053 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 695 - 704
Accepted on: Jul 2, 2019
Published on: Oct 21, 2019
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2019 Dzenana Eminagić, Aida Lokvančić, Berisa Hasanbegović, Alma Mekić-Abazović, Asmir Avdičević, Inga Marijanović, Slobodan M. Janković, Belma Kapo, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.